United States Gene Editing Market Insight
Published: 22 July 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The United States Gene Editing Market is projected to grow at a CAGR of around 15.2% over the forecast period, driven by increasing investments in genomic research and continuous advancements in precision medicine and biotechnology innovations.
United States Gene Editing Market Forecasts to 2035
- The United States Gene Editing Market size was estimated at approximately USD 4.85 Billion in 2025.
- The market is expected to grow at a CAGR of around 15.2% from 2025 to 2035.
- The United States Gene Editing Market is projected to reach approximately USD 19.90 Billion by 2035.
Notable Insights for the United States Gene Editing Market
- Segmentation based on technology indicates that CRISPR-Cas Systems, TALENs, and Zinc Finger Nucleases (ZFNs) account for nearly 74% of market revenue in 2025, supported by their widespread adoption in research, therapeutic development, and agricultural biotechnology applications.
- Segmentation based on application shows that Cell & Gene Therapy, Biomedical Research, and Drug Discovery & Development collectively hold nearly 81% market share in 2025, driven by growing demand for targeted genetic modifications and advanced therapeutic solutions.
- Growing adoption of next-generation gene editing platforms, precision genome engineering, AI-assisted genomic analysis, and personalized medicine initiatives contributes to more than 56% of new innovation activities in 2025.
- Rising prevalence of genetic disorders, increasing research funding, expanding clinical trials, and supportive regulatory frameworks account for nearly 63% of the key market growth drivers.
Download the eBook (ToC)
Research Methodologies Used to Analyze United States Gene Editing Market
The United States Gene Editing Market is analyzed using primary and secondary research methodologies to ensure accurate market estimates and forecasts. Primary research includes interviews with biotechnology companies, pharmaceutical manufacturers, genomic researchers, academic institutions, healthcare professionals, regulatory authorities, contract research organizations, and industry experts. Secondary research covers company annual reports, scientific publications, NIH databases, FDA reports, biotechnology journals, clinical trial registries, industry association reports, government databases, and market intelligence platforms. Data triangulation, competitive benchmarking, technology assessment, patent analysis, market share evaluation, regulatory analysis, and statistical forecasting models are applied to validate findings and provide reliable market forecasts through 2035.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States Gene Editing Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Gene Editing Market
- CRISPR Therapeutics AG
- Editas Medicine, Inc.
- Intellia Therapeutics, Inc.
- Beam Therapeutics Inc.
- Verve Therapeutics, Inc.
- Sangamo Therapeutics, Inc.
- Precision BioSciences, Inc.
- Caribou Biosciences, Inc.
- Thermo Fisher Scientific Inc.
- Danaher Corporation
Recent Developments:
- In May 2025, Intellia Therapeutics announced advancements in in vivo CRISPR-based gene editing programs targeting rare genetic diseases, supporting the expansion of precision medicine applications.
- In February 2025, Editas Medicine expanded its research collaborations focused on next-generation gene editing technologies aimed at improving editing accuracy and therapeutic outcomes.
Market Segmentation:
United States Gene Editing Market, By Technology
- CRISPR-Cas Systems
- TALENs
- Zinc Finger Nucleases (ZFNs)
- Base Editing
- Prime Editing
- Other Gene Editing Technologies
United States Gene Editing Market, By End-Use Industry
- Biotechnology Companies
- Pharmaceutical Companies
- Academic & Research Institutes
- Contract Research Organizations (CROs)
- Healthcare Institutions
United States Gene Editing Market, By Application
- Cell & Gene Therapy
- Drug Discovery & Development
- Biomedical Research
- Agricultural Biotechnology
- Industrial Biotechnology
Expert Views:
The United States Gene Editing Market is expected to witness substantial growth through 2035, driven by increasing genomic research activities, expanding clinical applications of gene editing technologies, and rising demand for precision medicine. Continued advancements in CRISPR, base editing, prime editing, and other genome engineering platforms are expected to improve therapeutic effectiveness, safety, and research efficiency. Growing investments in biotechnology innovation, gene therapy development, and personalized healthcare solutions will further accelerate market expansion. Additionally, supportive regulatory initiatives, increasing clinical trials, and expanding collaborations between research institutions and biotechnology companies are anticipated to create significant growth opportunities across the United States.
Author: Govind and Krishna By Decisions Advisors and Consulting